#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=A preliminary study of longitudinal neuroadaptation associated with recovery from addiction Background Few studies have explored longitudinal change in event-related brain responses during early recovery from addiction.
1-1	0-1	A	_
1-2	2-13	preliminary	_
1-3	14-19	study	_
1-4	20-22	of	_
1-5	23-35	longitudinal	_
1-6	36-51	neuroadaptation	_
1-7	52-62	associated	_
1-8	63-67	with	_
1-9	68-76	recovery	_
1-10	77-81	from	_
1-11	82-91	addiction	_
1-12	92-102	Background	_
1-13	103-106	Few	_
1-14	107-114	studies	_
1-15	115-119	have	_
1-16	120-128	explored	_
1-17	129-141	longitudinal	_
1-18	142-148	change	_
1-19	149-151	in	_
1-20	152-165	event-related	_
1-21	166-171	brain	_
1-22	172-181	responses	_
1-23	182-188	during	_
1-24	189-194	early	_
1-25	195-203	recovery	_
1-26	204-208	from	_
1-27	209-218	addiction	_
1-28	219-220	.	_

Text=Moreover, existing findings yield evidence of both increased and decreased signaling within reward and control centers over time.
2-1	221-229	Moreover	_
2-2	230-231	,	_
2-3	232-240	existing	_
2-4	241-249	findings	_
2-5	250-255	yield	_
2-6	256-264	evidence	_
2-7	265-267	of	_
2-8	268-272	both	_
2-9	273-282	increased	_
2-10	283-286	and	_
2-11	287-296	decreased	_
2-12	297-306	signaling	_
2-13	307-313	within	_
2-14	314-320	reward	_
2-15	321-324	and	_
2-16	325-332	control	_
2-17	333-340	centers	_
2-18	341-345	over	_
2-19	346-350	time	_
2-20	351-352	.	_

Text=The current study explored reward- and control-related signals in a risky decision-making task and specifically investigated parametric modulations of the BOLD signal, rather than signal magnitude alone.
3-1	353-356	The	_
3-2	357-364	current	_
3-3	365-370	study	_
3-4	371-379	explored	_
3-5	380-387	reward-	_
3-6	388-391	and	_
3-7	392-407	control-related	_
3-8	408-415	signals	_
3-9	416-418	in	_
3-10	419-420	a	_
3-11	421-426	risky	_
3-12	427-442	decision-making	_
3-13	443-447	task	_
3-14	448-451	and	_
3-15	452-464	specifically	_
3-16	465-477	investigated	_
3-17	478-488	parametric	_
3-18	489-500	modulations	_
3-19	501-503	of	_
3-20	504-507	the	_
3-21	508-512	BOLD	_
3-22	513-519	signal	_
3-23	520-521	,	_
3-24	522-528	rather	_
3-25	529-533	than	_
3-26	534-540	signal	_
3-27	541-550	magnitude	_
3-28	551-556	alone	_
3-29	557-558	.	_

Text=It was hypothesized that risk-related signals during decision-making and outcome evaluation would reflect recovery and that change in specific signals would correspond with improved treatment outcomes.
4-1	559-561	It	_
4-2	562-565	was	_
4-3	566-578	hypothesized	_
4-4	579-583	that	_
4-5	584-596	risk-related	_
4-6	597-604	signals	_
4-7	605-611	during	_
4-8	612-627	decision-making	_
4-9	628-631	and	_
4-10	632-639	outcome	_
4-11	640-650	evaluation	_
4-12	651-656	would	_
4-13	657-664	reflect	_
4-14	665-673	recovery	_
4-15	674-677	and	_
4-16	678-682	that	_
4-17	683-689	change	_
4-18	690-692	in	_
4-19	693-701	specific	_
4-20	702-709	signals	_
4-21	710-715	would	_
4-22	716-726	correspond	_
4-23	727-731	with	_
4-24	732-740	improved	_
4-25	741-750	treatment	_
4-26	751-759	outcomes	_
4-27	760-761	.	_

Text=Methods Twenty-one substance dependent individuals were recruited upon enrollment in community-based substance use treatment programs, wherein they received treatment-as-usual.
5-1	762-769	Methods	_
5-2	770-780	Twenty-one	_
5-3	781-790	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-4	791-800	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-5	801-812	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-6	813-817	were	_
5-7	818-827	recruited	_
5-8	828-832	upon	_
5-9	833-843	enrollment	_
5-10	844-846	in	_
5-11	847-862	community-based	_
5-12	863-872	substance	_
5-13	873-876	use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
5-14	877-886	treatment	_
5-15	887-895	programs	_
5-16	896-897	,	_
5-17	898-905	wherein	_
5-18	906-910	they	_
5-19	911-919	received	_
5-20	920-938	treatment-as-usual	_
5-21	939-940	.	_

Text=Participants completed functional neuroimaging assessments at baseline and 3-month follow-up while performing the Balloon Analogue Risk Task (BART).
6-1	941-953	Participants	_
6-2	954-963	completed	_
6-3	964-974	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
6-4	975-987	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
6-5	988-999	assessments	_
6-6	1000-1002	at	_
6-7	1003-1011	baseline	_
6-8	1012-1015	and	_
6-9	1016-1023	3-month	_
6-10	1024-1033	follow-up	_
6-11	1034-1039	while	_
6-12	1040-1050	performing	_
6-13	1051-1054	the	_
6-14	1055-1062	Balloon	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-15	1063-1071	Analogue	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-16	1072-1076	Risk	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-17	1077-1081	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-18	1082-1083	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-19	1084-1088	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-20	1089-1090	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
6-21	1091-1092	.	_

Text=Risk- and reward-sensitive signals were identified using parametric modulators.
7-1	1093-1098	Risk-	_
7-2	1099-1102	and	_
7-3	1103-1119	reward-sensitive	_
7-4	1120-1127	signals	_
7-5	1128-1132	were	_
7-6	1133-1143	identified	_
7-7	1144-1149	using	_
7-8	1150-1160	parametric	_
7-9	1161-1171	modulators	_
7-10	1172-1173	.	_

Text=Substance use was tracked throughout the 3-month study interval using the timeline follow-back procedure.
8-1	1174-1183	Substance	_
8-2	1184-1187	use	_
8-3	1188-1191	was	_
8-4	1192-1199	tracked	_
8-5	1200-1210	throughout	_
8-6	1211-1214	the	_
8-7	1215-1222	3-month	_
8-8	1223-1228	study	_
8-9	1229-1237	interval	_
8-10	1238-1243	using	_
8-11	1244-1247	the	_
8-12	1248-1256	timeline	_
8-13	1257-1268	follow-back	_
8-14	1269-1278	procedure	_
8-15	1279-1280	.	_

Text=Results Longitudinal contrasts of parametric modulators suggested improved formation of risk-informed outcome expectations at follow-up.
9-1	1281-1288	Results	_
9-2	1289-1301	Longitudinal	_
9-3	1302-1311	contrasts	_
9-4	1312-1314	of	_
9-5	1315-1325	parametric	_
9-6	1326-1336	modulators	_
9-7	1337-1346	suggested	_
9-8	1347-1355	improved	_
9-9	1356-1365	formation	_
9-10	1366-1368	of	_
9-11	1369-1382	risk-informed	_
9-12	1383-1390	outcome	_
9-13	1391-1403	expectations	_
9-14	1404-1406	at	_
9-15	1407-1416	follow-up	_
9-16	1417-1418	.	_

Text=Specifically, a greater response to high risk (low-likelihood) positive feedback was identified in caudal anterior cingulate cortex (ACC) and a greater response to low risk (low-likelihood) negative feedback was identified in caudal ACC and inferior frontal gyrus.
10-1	1419-1431	Specifically	_
10-2	1432-1433	,	_
10-3	1434-1435	a	_
10-4	1436-1443	greater	_
10-5	1444-1452	response	_
10-6	1453-1455	to	_
10-7	1456-1460	high	_
10-8	1461-1465	risk	_
10-9	1466-1467	(	_
10-10	1468-1482	low-likelihood	_
10-11	1483-1484	)	_
10-12	1485-1493	positive	_
10-13	1494-1502	feedback	_
10-14	1503-1506	was	_
10-15	1507-1517	identified	_
10-16	1518-1520	in	_
10-17	1521-1527	caudal	_
10-18	1528-1536	anterior	_
10-19	1537-1546	cingulate	_
10-20	1547-1553	cortex	_
10-21	1554-1555	(	_
10-22	1556-1559	ACC	_
10-23	1560-1561	)	_
10-24	1562-1565	and	_
10-25	1566-1567	a	_
10-26	1568-1575	greater	_
10-27	1576-1584	response	_
10-28	1585-1587	to	_
10-29	1588-1591	low	_
10-30	1592-1596	risk	_
10-31	1597-1598	(	_
10-32	1599-1613	low-likelihood	_
10-33	1614-1615	)	_
10-34	1616-1624	negative	_
10-35	1625-1633	feedback	_
10-36	1634-1637	was	_
10-37	1638-1648	identified	_
10-38	1649-1651	in	_
10-39	1652-1658	caudal	_
10-40	1659-1662	ACC	_
10-41	1663-1666	and	_
10-42	1667-1675	inferior	_
10-43	1676-1683	frontal	_
10-44	1684-1689	gyrus	_
10-45	1690-1691	.	_

Text=In addition, attenuation of a ventromedial prefrontal cortex (vmPFC) “ reward-seeking ” signal (i.e., increasing response with greater reward) during risky decisions at follow-up was associated with less substance use during the study interval.
11-1	1692-1694	In	_
11-2	1695-1703	addition	_
11-3	1704-1705	,	_
11-4	1706-1717	attenuation	_
11-5	1718-1720	of	_
11-6	1721-1722	a	_
11-7	1723-1735	ventromedial	_
11-8	1736-1746	prefrontal	_
11-9	1747-1753	cortex	_
11-10	1754-1755	(	_
11-11	1756-1761	vmPFC	_
11-12	1762-1763	)	_
11-13	1764-1765	“	_
11-14	1766-1780	reward-seeking	_
11-15	1781-1782	”	_
11-16	1783-1789	signal	_
11-17	1790-1791	(	_
11-18	1792-1796	i.e.	_
11-19	1797-1798	,	_
11-20	1799-1809	increasing	_
11-21	1810-1818	response	_
11-22	1819-1823	with	_
11-23	1824-1831	greater	_
11-24	1832-1838	reward	_
11-25	1839-1840	)	_
11-26	1841-1847	during	_
11-27	1848-1853	risky	_
11-28	1854-1863	decisions	_
11-29	1864-1866	at	_
11-30	1867-1876	follow-up	_
11-31	1877-1880	was	_
11-32	1881-1891	associated	_
11-33	1892-1896	with	_
11-34	1897-1901	less	_
11-35	1902-1911	substance	_
11-36	1912-1915	use	_
11-37	1916-1922	during	_
11-38	1923-1926	the	_
11-39	1927-1932	study	_
11-40	1933-1941	interval	_
11-41	1942-1943	.	_

Text=Conclusions Changes in risk- and reward-related signaling in ACC/vmPFC appear to reflect recovery and may support sobriety.
12-1	1944-1955	Conclusions	_
12-2	1956-1963	Changes	_
12-3	1964-1966	in	_
12-4	1967-1972	risk-	_
12-5	1973-1976	and	_
12-6	1977-1991	reward-related	_
12-7	1992-2001	signaling	_
12-8	2002-2004	in	_
12-9	2005-2014	ACC/vmPFC	_
12-10	2015-2021	appear	_
12-11	2022-2024	to	_
12-12	2025-2032	reflect	_
12-13	2033-2041	recovery	_
12-14	2042-2045	and	_
12-15	2046-2049	may	_
12-16	2050-2057	support	_
12-17	2058-2066	sobriety	_
12-18	2067-2068	.	_

Text=2.
13-1	2069-2070	2	_
13-2	2071-2072	.	_

Text=Methods 2.1.
14-1	2073-2080	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2081-2084	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2085-2086	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=Participants and design Twenty-six SDIs were enrolled upon treatment engagement at one of two community-based clinics; 21 completed baseline and follow-up assessments and are included in the current sample (6 female; see Table 1 for demographic and recruitment data).
15-1	2087-2099	Participants	_
15-2	2100-2103	and	_
15-3	2104-2110	design	_
15-4	2111-2121	Twenty-six	_
15-5	2122-2126	SDIs	_
15-6	2127-2131	were	_
15-7	2132-2140	enrolled	_
15-8	2141-2145	upon	_
15-9	2146-2155	treatment	_
15-10	2156-2166	engagement	_
15-11	2167-2169	at	_
15-12	2170-2173	one	_
15-13	2174-2176	of	_
15-14	2177-2180	two	_
15-15	2181-2196	community-based	_
15-16	2197-2204	clinics	_
15-17	2205-2206	;	_
15-18	2207-2209	21	_
15-19	2210-2219	completed	_
15-20	2220-2228	baseline	_
15-21	2229-2232	and	_
15-22	2233-2242	follow-up	_
15-23	2243-2254	assessments	_
15-24	2255-2258	and	_
15-25	2259-2262	are	_
15-26	2263-2271	included	_
15-27	2272-2274	in	_
15-28	2275-2278	the	_
15-29	2279-2286	current	_
15-30	2287-2293	sample	_
15-31	2294-2295	(	_
15-32	2296-2297	6	_
15-33	2298-2304	female	_
15-34	2305-2306	;	_
15-35	2307-2310	see	_
15-36	2311-2316	Table	_
15-37	2317-2318	1	_
15-38	2319-2322	for	_
15-39	2323-2334	demographic	_
15-40	2335-2338	and	_
15-41	2339-2350	recruitment	_
15-42	2351-2355	data	_
15-43	2356-2357	)	_
15-44	2358-2359	.	_

Text=Participants were (1) diagnosed with alcohol, drug, or polysubstance dependence using DSM-IV criteria, (2) 18–50 years of age, (3) 1–4 weeks abstinent at time of baseline assessment, and (4) actively participating in substance use treatment.
16-1	2360-2372	Participants	_
16-2	2373-2377	were	_
16-3	2378-2379	(	_
16-4	2380-2381	1	_
16-5	2382-2383	)	_
16-6	2384-2393	diagnosed	_
16-7	2394-2398	with	_
16-8	2399-2406	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
16-9	2407-2408	,	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
16-10	2409-2413	drug	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
16-11	2414-2415	,	_
16-12	2416-2418	or	_
16-13	2419-2432	polysubstance	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
16-14	2433-2443	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
16-15	2444-2449	using	_
16-16	2450-2456	DSM-IV	_
16-17	2457-2465	criteria	_
16-18	2466-2467	,	_
16-19	2468-2469	(	_
16-20	2470-2471	2	_
16-21	2472-2473	)	_
16-22	2474-2479	18–50	_
16-23	2480-2485	years	_
16-24	2486-2488	of	_
16-25	2489-2492	age	_
16-26	2493-2494	,	_
16-27	2495-2496	(	_
16-28	2497-2498	3	_
16-29	2499-2500	)	_
16-30	2501-2504	1–4	_
16-31	2505-2510	weeks	_
16-32	2511-2520	abstinent	_
16-33	2521-2523	at	_
16-34	2524-2528	time	_
16-35	2529-2531	of	_
16-36	2532-2540	baseline	_
16-37	2541-2551	assessment	_
16-38	2552-2553	,	_
16-39	2554-2557	and	_
16-40	2558-2559	(	_
16-41	2560-2561	4	_
16-42	2562-2563	)	_
16-43	2564-2572	actively	_
16-44	2573-2586	participating	_
16-45	2587-2589	in	_
16-46	2590-2599	substance	_
16-47	2600-2603	use	_
16-48	2604-2613	treatment	_
16-49	2614-2615	.	_

Text=Individuals receiving replacement pharmacotherapy and those reporting contraindications to magnetic resonance imaging or a history of traumatic brain injury, other neurocognitive disorders, Bipolar disorder, or psychotic illness were excluded.
17-1	2616-2627	Individuals	_
17-2	2628-2637	receiving	_
17-3	2638-2649	replacement	_
17-4	2650-2665	pharmacotherapy	_
17-5	2666-2669	and	_
17-6	2670-2675	those	_
17-7	2676-2685	reporting	_
17-8	2686-2703	contraindications	_
17-9	2704-2706	to	_
17-10	2707-2715	magnetic	_
17-11	2716-2725	resonance	_
17-12	2726-2733	imaging	_
17-13	2734-2736	or	_
17-14	2737-2738	a	_
17-15	2739-2746	history	_
17-16	2747-2749	of	_
17-17	2750-2759	traumatic	_
17-18	2760-2765	brain	_
17-19	2766-2772	injury	_
17-20	2773-2774	,	_
17-21	2775-2780	other	_
17-22	2781-2795	neurocognitive	_
17-23	2796-2805	disorders	_
17-24	2806-2807	,	_
17-25	2808-2815	Bipolar	_
17-26	2816-2824	disorder	_
17-27	2825-2826	,	_
17-28	2827-2829	or	_
17-29	2830-2839	psychotic	_
17-30	2840-2847	illness	_
17-31	2848-2852	were	_
17-32	2853-2861	excluded	_
17-33	2862-2863	.	_

Text=Participants received treatment-as-usual in an intensive outpatient or residential treatment program.
18-1	2864-2876	Participants	_
18-2	2877-2885	received	_
18-3	2886-2904	treatment-as-usual	_
18-4	2905-2907	in	_
18-5	2908-2910	an	_
18-6	2911-2920	intensive	_
18-7	2921-2931	outpatient	_
18-8	2932-2934	or	_
18-9	2935-2946	residential	_
18-10	2947-2956	treatment	_
18-11	2957-2964	program	_
18-12	2965-2966	.	_

Text=Both programs were abstinence-oriented and utilized a twelve-step facilitation approach, as well as routine urinalysis (see Supplementary materials for additional details).
19-1	2967-2971	Both	_
19-2	2972-2980	programs	_
19-3	2981-2985	were	_
19-4	2986-3005	abstinence-oriented	_
19-5	3006-3009	and	_
19-6	3010-3018	utilized	_
19-7	3019-3020	a	_
19-8	3021-3032	twelve-step	_
19-9	3033-3045	facilitation	_
19-10	3046-3054	approach	_
19-11	3055-3056	,	_
19-12	3057-3059	as	_
19-13	3060-3064	well	_
19-14	3065-3067	as	_
19-15	3068-3075	routine	_
19-16	3076-3086	urinalysis	_
19-17	3087-3088	(	_
19-18	3089-3092	see	_
19-19	3093-3106	Supplementary	_
19-20	3107-3116	materials	_
19-21	3117-3120	for	_
19-22	3121-3131	additional	_
19-23	3132-3139	details	_
19-24	3140-3141	)	_
19-25	3142-3143	.	_

Text=Participants completed a baseline assessment and follow-up fMRI assessment at 3-months.
20-1	3144-3156	Participants	_
20-2	3157-3166	completed	_
20-3	3167-3168	a	_
20-4	3169-3177	baseline	_
20-5	3178-3188	assessment	_
20-6	3189-3192	and	_
20-7	3193-3202	follow-up	_
20-8	3203-3207	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
20-9	3208-3218	assessment	_
20-10	3219-3221	at	_
20-11	3222-3230	3-months	_
20-12	3231-3232	.	_

Text=The timeline follow-back procedure was conducted at monthly intervals to track drug and alcohol use during the 3-month period and additional narrative details (e.g., subjective intoxication) were also collected (see Supplementary materials for additional information).
21-1	3233-3236	The	_
21-2	3237-3245	timeline	_
21-3	3246-3257	follow-back	_
21-4	3258-3267	procedure	_
21-5	3268-3271	was	_
21-6	3272-3281	conducted	_
21-7	3282-3284	at	_
21-8	3285-3292	monthly	_
21-9	3293-3302	intervals	_
21-10	3303-3305	to	_
21-11	3306-3311	track	_
21-12	3312-3316	drug	_
21-13	3317-3320	and	_
21-14	3321-3328	alcohol	_
21-15	3329-3332	use	_
21-16	3333-3339	during	_
21-17	3340-3343	the	_
21-18	3344-3351	3-month	_
21-19	3352-3358	period	_
21-20	3359-3362	and	_
21-21	3363-3373	additional	_
21-22	3374-3383	narrative	_
21-23	3384-3391	details	_
21-24	3392-3393	(	_
21-25	3394-3398	e.g.	_
21-26	3399-3400	,	_
21-27	3401-3411	subjective	_
21-28	3412-3424	intoxication	_
21-29	3425-3426	)	_
21-30	3427-3431	were	_
21-31	3432-3436	also	_
21-32	3437-3446	collected	_
21-33	3447-3448	(	_
21-34	3449-3452	see	_
21-35	3453-3466	Supplementary	_
21-36	3467-3476	materials	_
21-37	3477-3480	for	_
21-38	3481-3491	additional	_
21-39	3492-3503	information	_
21-40	3504-3505	)	_
21-41	3506-3507	.	_

Text=A breathalyzer test (AlcoSensor IV, Intoximeters, Inc., St. Louis, MO) and 6-panel urine drug screen (Alere Toxicology, Portsmouth, VA) were conducted prior to baseline and 3-month assessments.
22-1	3508-3509	A	_
22-2	3510-3522	breathalyzer	_
22-3	3523-3527	test	_
22-4	3528-3529	(	_
22-5	3530-3540	AlcoSensor	_
22-6	3541-3543	IV	_
22-7	3544-3545	,	_
22-8	3546-3558	Intoximeters	_
22-9	3559-3560	,	_
22-10	3561-3565	Inc.	_
22-11	3566-3567	,	_
22-12	3568-3571	St.	_
22-13	3572-3577	Louis	_
22-14	3578-3579	,	_
22-15	3580-3582	MO	_
22-16	3583-3584	)	_
22-17	3585-3588	and	_
22-18	3589-3596	6-panel	_
22-19	3597-3602	urine	_
22-20	3603-3607	drug	_
22-21	3608-3614	screen	_
22-22	3615-3616	(	_
22-23	3617-3622	Alere	_
22-24	3623-3633	Toxicology	_
22-25	3634-3635	,	_
22-26	3636-3646	Portsmouth	_
22-27	3647-3648	,	_
22-28	3649-3651	VA	_
22-29	3652-3653	)	_
22-30	3654-3658	were	_
22-31	3659-3668	conducted	_
22-32	3669-3674	prior	_
22-33	3675-3677	to	_
22-34	3678-3686	baseline	_
22-35	3687-3690	and	_
22-36	3691-3698	3-month	_
22-37	3699-3710	assessments	_
22-38	3711-3712	.	_

Text=Participants who resumed use during the study were required to maintain abstinence for 48 h prior to testing and were evaluated for signs of intoxication.
23-1	3713-3725	Participants	_
23-2	3726-3729	who	_
23-3	3730-3737	resumed	_
23-4	3738-3741	use	_
23-5	3742-3748	during	_
23-6	3749-3752	the	_
23-7	3753-3758	study	_
23-8	3759-3763	were	_
23-9	3764-3772	required	_
23-10	3773-3775	to	_
23-11	3776-3784	maintain	_
23-12	3785-3795	abstinence	_
23-13	3796-3799	for	_
23-14	3800-3802	48	_
23-15	3803-3804	h	_
23-16	3805-3810	prior	_
23-17	3811-3813	to	_
23-18	3814-3821	testing	_
23-19	3822-3825	and	_
23-20	3826-3830	were	_
23-21	3831-3840	evaluated	_
23-22	3841-3844	for	_
23-23	3845-3850	signs	_
23-24	3851-3853	of	_
23-25	3854-3866	intoxication	_
23-26	3867-3868	.	_

Text=Study assessments were not conducted if urinalysis results were positive for recent substance use or blood alcohol content was greater than 0.000 percent by volume.
24-1	3869-3874	Study	_
24-2	3875-3886	assessments	_
24-3	3887-3891	were	_
24-4	3892-3895	not	_
24-5	3896-3905	conducted	_
24-6	3906-3908	if	_
24-7	3909-3919	urinalysis	_
24-8	3920-3927	results	_
24-9	3928-3932	were	_
24-10	3933-3941	positive	_
24-11	3942-3945	for	_
24-12	3946-3952	recent	_
24-13	3953-3962	substance	_
24-14	3963-3966	use	_
24-15	3967-3969	or	_
24-16	3970-3975	blood	_
24-17	3976-3983	alcohol	_
24-18	3984-3991	content	_
24-19	3992-3995	was	_
24-20	3996-4003	greater	_
24-21	4004-4008	than	_
24-22	4009-4014	0.000	_
24-23	4015-4022	percent	_
24-24	4023-4025	by	_
24-25	4026-4032	volume	_
24-26	4033-4034	.	_

Text=Two participants screened positive for use at 3-month follow-up; both were rescheduled and completed this assessment after providing negative urine specimen and breathalyzer results.
25-1	4035-4038	Two	_
25-2	4039-4051	participants	_
25-3	4052-4060	screened	_
25-4	4061-4069	positive	_
25-5	4070-4073	for	_
25-6	4074-4077	use	_
25-7	4078-4080	at	_
25-8	4081-4088	3-month	_
25-9	4089-4098	follow-up	_
25-10	4099-4100	;	_
25-11	4101-4105	both	_
25-12	4106-4110	were	_
25-13	4111-4122	rescheduled	_
25-14	4123-4126	and	_
25-15	4127-4136	completed	_
25-16	4137-4141	this	_
25-17	4142-4152	assessment	_
25-18	4153-4158	after	_
25-19	4159-4168	providing	_
25-20	4169-4177	negative	_
25-21	4178-4183	urine	_
25-22	4184-4192	specimen	_
25-23	4193-4196	and	_
25-24	4197-4209	breathalyzer	_
25-25	4210-4217	results	_
25-26	4218-4219	.	_

Text=Lifetime problems with alcohol and other substances were assessed at baseline using the Semi-structured Assessment for the Genetics of Alcoholism.
26-1	4220-4228	Lifetime	_
26-2	4229-4237	problems	_
26-3	4238-4242	with	_
26-4	4243-4250	alcohol	_
26-5	4251-4254	and	_
26-6	4255-4260	other	_
26-7	4261-4271	substances	_
26-8	4272-4276	were	_
26-9	4277-4285	assessed	_
26-10	4286-4288	at	_
26-11	4289-4297	baseline	_
26-12	4298-4303	using	_
26-13	4304-4307	the	_
26-14	4308-4323	Semi-structured	_
26-15	4324-4334	Assessment	_
26-16	4335-4338	for	_
26-17	4339-4342	the	_
26-18	4343-4351	Genetics	_
26-19	4352-4354	of	_
26-20	4355-4365	Alcoholism	_
26-21	4366-4367	.	_

Text=Data from the timeline follow-back were used to compute a substance use metric (SUM),1 summarizing days of use (with and without intoxication) for each participant; values were arcsine-transformed to better approximate the normal distribution.
27-1	4368-4372	Data	_
27-2	4373-4377	from	_
27-3	4378-4381	the	_
27-4	4382-4390	timeline	_
27-5	4391-4402	follow-back	_
27-6	4403-4407	were	_
27-7	4408-4412	used	_
27-8	4413-4415	to	_
27-9	4416-4423	compute	_
27-10	4424-4425	a	_
27-11	4426-4435	substance	_
27-12	4436-4439	use	_
27-13	4440-4446	metric	_
27-14	4447-4448	(	_
27-15	4449-4452	SUM	_
27-16	4453-4454	)	_
27-17	4455-4457	,1	_
27-18	4458-4469	summarizing	_
27-19	4470-4474	days	_
27-20	4475-4477	of	_
27-21	4478-4481	use	_
27-22	4482-4483	(	_
27-23	4484-4488	with	_
27-24	4489-4492	and	_
27-25	4493-4500	without	_
27-26	4501-4513	intoxication	_
27-27	4514-4515	)	_
27-28	4516-4519	for	_
27-29	4520-4524	each	_
27-30	4525-4536	participant	_
27-31	4537-4538	;	_
27-32	4539-4545	values	_
27-33	4546-4550	were	_
27-34	4551-4570	arcsine-transformed	_
27-35	4571-4573	to	_
27-36	4574-4580	better	_
27-37	4581-4592	approximate	_
27-38	4593-4596	the	_
27-39	4597-4603	normal	_
27-40	4604-4616	distribution	_
27-41	4617-4618	.	_

Text=Additional self-report (including measures of social investment, craving, anxiety, depression, and coping) and cognitive-behavioral (i.e., Go/No-Go, Delay Discounting, and Brown-Peterson tasks) measures of recovery are described in Supplementary materials and Supplementary Table 1.
28-1	4619-4629	Additional	_
28-2	4630-4641	self-report	_
28-3	4642-4643	(	_
28-4	4644-4653	including	_
28-5	4654-4662	measures	_
28-6	4663-4665	of	_
28-7	4666-4672	social	_
28-8	4673-4683	investment	_
28-9	4684-4685	,	_
28-10	4686-4693	craving	_
28-11	4694-4695	,	_
28-12	4696-4703	anxiety	_
28-13	4704-4705	,	_
28-14	4706-4716	depression	_
28-15	4717-4718	,	_
28-16	4719-4722	and	_
28-17	4723-4729	coping	_
28-18	4730-4731	)	_
28-19	4732-4735	and	_
28-20	4736-4756	cognitive-behavioral	_
28-21	4757-4758	(	_
28-22	4759-4763	i.e.	_
28-23	4764-4765	,	_
28-24	4766-4774	Go/No-Go	_
28-25	4775-4776	,	_
28-26	4777-4782	Delay	_
28-27	4783-4794	Discounting	_
28-28	4795-4796	,	_
28-29	4797-4800	and	_
28-30	4801-4815	Brown-Peterson	_
28-31	4816-4821	tasks	_
28-32	4822-4823	)	_
28-33	4824-4832	measures	_
28-34	4833-4835	of	_
28-35	4836-4844	recovery	_
28-36	4845-4848	are	_
28-37	4849-4858	described	_
28-38	4859-4861	in	_
28-39	4862-4875	Supplementary	_
28-40	4876-4885	materials	_
28-41	4886-4889	and	_
28-42	4890-4903	Supplementary	_
28-43	4904-4909	Table	_
28-44	4910-4911	1	_
28-45	4912-4913	.	_

Text=2.2. fMRI procedure Imaging datasets were acquired at baseline and 3-month follow-up using a Siemens Magnetom Trio 3-T MRI scanner and 32-channel head coil.
29-1	4914-4918	2.2.	_
29-2	4919-4923	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-3	4924-4933	procedure	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-4	4934-4941	Imaging	_
29-5	4942-4950	datasets	_
29-6	4951-4955	were	_
29-7	4956-4964	acquired	_
29-8	4965-4967	at	_
29-9	4968-4976	baseline	_
29-10	4977-4980	and	_
29-11	4981-4988	3-month	_
29-12	4989-4998	follow-up	_
29-13	4999-5004	using	_
29-14	5005-5006	a	_
29-15	5007-5014	Siemens	_
29-16	5015-5023	Magnetom	_
29-17	5024-5028	Trio	_
29-18	5029-5032	3-T	_
29-19	5033-5036	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-20	5037-5044	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-21	5045-5048	and	_
29-22	5049-5059	32-channel	_
29-23	5060-5064	head	_
29-24	5065-5069	coil	_
29-25	5070-5071	.	_

Text=We used a version of the BART (see Fig.
30-1	5072-5074	We	_
30-2	5075-5079	used	_
30-3	5080-5081	a	_
30-4	5082-5089	version	_
30-5	5090-5092	of	_
30-6	5093-5096	the	_
30-7	5097-5101	BART	_
30-8	5102-5103	(	_
30-9	5104-5107	see	_
30-10	5108-5111	Fig	_
30-11	5112-5113	.	_

Text=1), previously validated in neuroimaging studies of healthy individuals, substance users, and at-risk youth, developed from the original implementation of the BART for fMRI and utilizing a similar analytic approach.
31-1	5114-5115	1	_
31-2	5116-5117	)	_
31-3	5118-5119	,	_
31-4	5120-5130	previously	_
31-5	5131-5140	validated	_
31-6	5141-5143	in	_
31-7	5144-5156	neuroimaging	_
31-8	5157-5164	studies	_
31-9	5165-5167	of	_
31-10	5168-5175	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-11	5176-5187	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
31-12	5188-5189	,	_
31-13	5190-5199	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
31-14	5200-5205	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
31-15	5206-5207	,	_
31-16	5208-5211	and	_
31-17	5212-5219	at-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
31-18	5220-5225	youth	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
31-19	5226-5227	,	_
31-20	5228-5237	developed	_
31-21	5238-5242	from	_
31-22	5243-5246	the	_
31-23	5247-5255	original	_
31-24	5256-5270	implementation	_
31-25	5271-5273	of	_
31-26	5274-5277	the	_
31-27	5278-5282	BART	_
31-28	5283-5286	for	_
31-29	5287-5291	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-30	5292-5295	and	_
31-31	5296-5305	utilizing	_
31-32	5306-5307	a	_
31-33	5308-5315	similar	_
31-34	5316-5324	analytic	_
31-35	5325-5333	approach	_
31-36	5334-5335	.	_

Text=Acquisition parameters were identical to those used in and are reported in Supplementary materials.
32-1	5336-5347	Acquisition	_
32-2	5348-5358	parameters	_
32-3	5359-5363	were	_
32-4	5364-5373	identical	_
32-5	5374-5376	to	_
32-6	5377-5382	those	_
32-7	5383-5387	used	_
32-8	5388-5390	in	_
32-9	5391-5394	and	_
32-10	5395-5398	are	_
32-11	5399-5407	reported	_
32-12	5408-5410	in	_
32-13	5411-5424	Supplementary	_
32-14	5425-5434	materials	_
32-15	5435-5436	.	_

Text=Stimuli were presented using E-Prime (Psychology Software Tools, Pittsburgh, PA) and a projector to display images within the scanner bore.
33-1	5437-5444	Stimuli	_
33-2	5445-5449	were	_
33-3	5450-5459	presented	_
33-4	5460-5465	using	_
33-5	5466-5473	E-Prime	_
33-6	5474-5475	(	_
33-7	5476-5486	Psychology	_
33-8	5487-5495	Software	_
33-9	5496-5501	Tools	_
33-10	5502-5503	,	_
33-11	5504-5514	Pittsburgh	_
33-12	5515-5516	,	_
33-13	5517-5519	PA	_
33-14	5520-5521	)	_
33-15	5522-5525	and	_
33-16	5526-5527	a	_
33-17	5528-5537	projector	_
33-18	5538-5540	to	_
33-19	5541-5548	display	_
33-20	5549-5555	images	_
33-21	5556-5562	within	_
33-22	5563-5566	the	_
33-23	5567-5574	scanner	_
33-24	5575-5579	bore	_
33-25	5580-5581	.	_

Text=Each inflation sequence began with a small balloon, valued at $0.00, in the center of the screen.
34-1	5582-5586	Each	_
34-2	5587-5596	inflation	_
34-3	5597-5605	sequence	_
34-4	5606-5611	began	_
34-5	5612-5616	with	_
34-6	5617-5618	a	_
34-7	5619-5624	small	_
34-8	5625-5632	balloon	_
34-9	5633-5634	,	_
34-10	5635-5641	valued	_
34-11	5642-5644	at	_
34-12	5645-5646	$	_
34-13	5647-5651	0.00	_
34-14	5652-5653	,	_
34-15	5654-5656	in	_
34-16	5657-5660	the	_
34-17	5661-5667	center	_
34-18	5668-5670	of	_
34-19	5671-5674	the	_
34-20	5675-5681	screen	_
34-21	5682-5683	.	_

Text=Participants could 'Inflate' the balloon, increasing its value in the next trial, or 'Redeem' the balloon for its current value by responding with left and right index fingers (assignment counterbalanced across participants).
35-1	5684-5696	Participants	_
35-2	5697-5702	could	_
35-3	5703-5711	'Inflate	_
35-4	5712-5713	'	_
35-5	5714-5717	the	_
35-6	5718-5725	balloon	_
35-7	5726-5727	,	_
35-8	5728-5738	increasing	_
35-9	5739-5742	its	_
35-10	5743-5748	value	_
35-11	5749-5751	in	_
35-12	5752-5755	the	_
35-13	5756-5760	next	_
35-14	5761-5766	trial	_
35-15	5767-5768	,	_
35-16	5769-5771	or	_
35-17	5772-5779	'Redeem	_
35-18	5780-5781	'	_
35-19	5782-5785	the	_
35-20	5786-5793	balloon	_
35-21	5794-5797	for	_
35-22	5798-5801	its	_
35-23	5802-5809	current	_
35-24	5810-5815	value	_
35-25	5816-5818	by	_
35-26	5819-5829	responding	_
35-27	5830-5834	with	_
35-28	5835-5839	left	_
35-29	5840-5843	and	_
35-30	5844-5849	right	_
35-31	5850-5855	index	_
35-32	5856-5863	fingers	_
35-33	5864-5865	(	_
35-34	5866-5876	assignment	_
35-35	5877-5892	counterbalanced	_
35-36	5893-5899	across	_
35-37	5900-5912	participants	_
35-38	5913-5914	)	_
35-39	5915-5916	.	_

Text=Each decision was preceded by a red rectangle, presented below the balloon for a pseudo-randomly-determined delay of 1.5, 2, or 2.5 s, signaling participants to withhold responses.
36-1	5917-5921	Each	_
36-2	5922-5930	decision	_
36-3	5931-5934	was	_
36-4	5935-5943	preceded	_
36-5	5944-5946	by	_
36-6	5947-5948	a	_
36-7	5949-5952	red	_
36-8	5953-5962	rectangle	_
36-9	5963-5964	,	_
36-10	5965-5974	presented	_
36-11	5975-5980	below	_
36-12	5981-5984	the	_
36-13	5985-5992	balloon	_
36-14	5993-5996	for	_
36-15	5997-5998	a	_
36-16	5999-6025	pseudo-randomly-determined	_
36-17	6026-6031	delay	_
36-18	6032-6034	of	_
36-19	6035-6038	1.5	_
36-20	6039-6040	,	_
36-21	6041-6042	2	_
36-22	6043-6044	,	_
36-23	6045-6047	or	_
36-24	6048-6051	2.5	_
36-25	6052-6053	s	_
36-26	6054-6055	,	_
36-27	6056-6065	signaling	_
36-28	6066-6078	participants	_
36-29	6079-6081	to	_
36-30	6082-6090	withhold	_
36-31	6091-6100	responses	_
36-32	6101-6102	.	_

Text=The rectangle then turned green, indicating participants could respond when ready.
37-1	6103-6106	The	_
37-2	6107-6116	rectangle	_
37-3	6117-6121	then	_
37-4	6122-6128	turned	_
37-5	6129-6134	green	_
37-6	6135-6136	,	_
37-7	6137-6147	indicating	_
37-8	6148-6160	participants	_
37-9	6161-6166	could	_
37-10	6167-6174	respond	_
37-11	6175-6179	when	_
37-12	6180-6185	ready	_
37-13	6186-6187	.	_

Text=Following response production, a jittered delay of 0–6 s preceded feedback such that decision and outcome intervals could be estimated separately in the general linear model (GLM).
38-1	6188-6197	Following	_
38-2	6198-6206	response	_
38-3	6207-6217	production	_
38-4	6218-6219	,	_
38-5	6220-6221	a	_
38-6	6222-6230	jittered	_
38-7	6231-6236	delay	_
38-8	6237-6239	of	_
38-9	6240-6243	0–6	_
38-10	6244-6245	s	_
38-11	6246-6254	preceded	_
38-12	6255-6263	feedback	_
38-13	6264-6268	such	_
38-14	6269-6273	that	_
38-15	6274-6282	decision	_
38-16	6283-6286	and	_
38-17	6287-6294	outcome	_
38-18	6295-6304	intervals	_
38-19	6305-6310	could	_
38-20	6311-6313	be	_
38-21	6314-6323	estimated	_
38-22	6324-6334	separately	_
38-23	6335-6337	in	_
38-24	6338-6341	the	_
38-25	6342-6349	general	_
38-26	6350-6356	linear	_
38-27	6357-6362	model	_
38-28	6363-6364	(	_
38-29	6365-6368	GLM	_
38-30	6369-6370	)	_
38-31	6371-6372	.	_

Text=After 'Redeem' responses, the words, “ You Win! ” were presented for 1 s ('Win') and the wager value was added to block winnings (visible at bottom of screen).
39-1	6373-6378	After	_
39-2	6379-6386	'Redeem	_
39-3	6387-6388	'	_
39-4	6389-6398	responses	_
39-5	6399-6400	,	_
39-6	6401-6404	the	_
39-7	6405-6410	words	_
39-8	6411-6412	,	_
39-9	6413-6414	“	_
39-10	6415-6418	You	_
39-11	6419-6422	Win	_
39-12	6423-6424	!	_
39-13	6425-6426	”	_
39-14	6427-6431	were	_
39-15	6432-6441	presented	_
39-16	6442-6445	for	_
39-17	6446-6447	1	_
39-18	6448-6449	s	_
39-19	6450-6451	(	_
39-20	6452-6456	'Win	_
39-21	6457-6458	'	_
39-22	6459-6460	)	_
39-23	6461-6464	and	_
39-24	6465-6468	the	_
39-25	6469-6474	wager	_
39-26	6475-6480	value	_
39-27	6481-6484	was	_
39-28	6485-6490	added	_
39-29	6491-6493	to	_
39-30	6494-6499	block	_
39-31	6500-6508	winnings	_
39-32	6509-6510	(	_
39-33	6511-6518	visible	_
39-34	6519-6521	at	_
39-35	6522-6528	bottom	_
39-36	6529-6531	of	_
39-37	6532-6538	screen	_
39-38	6539-6540	)	_
39-39	6541-6542	.	_

Text=After 'Inflate' responses, 'Success' was signaled by an increased wager value and balloon size, cueing the start of the next decision trial.
40-1	6543-6548	After	_
40-2	6549-6557	'Inflate	_
40-3	6558-6559	'	_
40-4	6560-6569	responses	_
40-5	6570-6571	,	_
40-6	6572-6580	'Success	_
40-7	6581-6582	'	_
40-8	6583-6586	was	_
40-9	6587-6595	signaled	_
40-10	6596-6598	by	_
40-11	6599-6601	an	_
40-12	6602-6611	increased	_
40-13	6612-6617	wager	_
40-14	6618-6623	value	_
40-15	6624-6627	and	_
40-16	6628-6635	balloon	_
40-17	6636-6640	size	_
40-18	6641-6642	,	_
40-19	6643-6649	cueing	_
40-20	6650-6653	the	_
40-21	6654-6659	start	_
40-22	6660-6662	of	_
40-23	6663-6666	the	_
40-24	6667-6671	next	_
40-25	6672-6680	decision	_
40-26	6681-6686	trial	_
40-27	6687-6688	.	_

Text=Alternatively, an 'Explode' outcome (resulting in loss of the current wager) was signaled by presentation of an exploding balloon for 500 ms and the words, “ You Lose! ” for 1 s. An equiprobable delay of 2, 4, or 6 s preceded new inflation sequences, signaled by presentation of a new $0.00 balloon after 'Win' and 'Explode' events.
41-1	6689-6702	Alternatively	_
41-2	6703-6704	,	_
41-3	6705-6707	an	_
41-4	6708-6716	'Explode	_
41-5	6717-6718	'	_
41-6	6719-6726	outcome	_
41-7	6727-6728	(	_
41-8	6729-6738	resulting	_
41-9	6739-6741	in	_
41-10	6742-6746	loss	_
41-11	6747-6749	of	_
41-12	6750-6753	the	_
41-13	6754-6761	current	_
41-14	6762-6767	wager	_
41-15	6768-6769	)	_
41-16	6770-6773	was	_
41-17	6774-6782	signaled	_
41-18	6783-6785	by	_
41-19	6786-6798	presentation	_
41-20	6799-6801	of	_
41-21	6802-6804	an	_
41-22	6805-6814	exploding	_
41-23	6815-6822	balloon	_
41-24	6823-6826	for	_
41-25	6827-6830	500	_
41-26	6831-6833	ms	_
41-27	6834-6837	and	_
41-28	6838-6841	the	_
41-29	6842-6847	words	_
41-30	6848-6849	,	_
41-31	6850-6851	“	_
41-32	6852-6855	You	_
41-33	6856-6860	Lose	_
41-34	6861-6862	!	_
41-35	6863-6864	”	_
41-36	6865-6868	for	_
41-37	6869-6870	1	_
41-38	6871-6873	s.	_
41-39	6874-6876	An	_
41-40	6877-6889	equiprobable	_
41-41	6890-6895	delay	_
41-42	6896-6898	of	_
41-43	6899-6900	2	_
41-44	6901-6902	,	_
41-45	6903-6904	4	_
41-46	6905-6906	,	_
41-47	6907-6909	or	_
41-48	6910-6911	6	_
41-49	6912-6913	s	_
41-50	6914-6922	preceded	_
41-51	6923-6926	new	_
41-52	6927-6936	inflation	_
41-53	6937-6946	sequences	_
41-54	6947-6948	,	_
41-55	6949-6957	signaled	_
41-56	6958-6960	by	_
41-57	6961-6973	presentation	_
41-58	6974-6976	of	_
41-59	6977-6978	a	_
41-60	6979-6982	new	_
41-61	6983-6984	$	_
41-62	6985-6989	0.00	_
41-63	6990-6997	balloon	_
41-64	6998-7003	after	_
41-65	7004-7008	'Win	_
41-66	7009-7010	'	_
41-67	7011-7014	and	_
41-68	7015-7023	'Explode	_
41-69	7024-7025	'	_
41-70	7026-7032	events	_
41-71	7033-7034	.	_

Text=Explosion probability and reward increased in parallel with each inflation, in accordance with values specified in Table 2.
42-1	7035-7044	Explosion	_
42-2	7045-7056	probability	_
42-3	7057-7060	and	_
42-4	7061-7067	reward	_
42-5	7068-7077	increased	_
42-6	7078-7080	in	_
42-7	7081-7089	parallel	_
42-8	7090-7094	with	_
42-9	7095-7099	each	_
42-10	7100-7109	inflation	_
42-11	7110-7111	,	_
42-12	7112-7114	in	_
42-13	7115-7125	accordance	_
42-14	7126-7130	with	_
42-15	7131-7137	values	_
42-16	7138-7147	specified	_
42-17	7148-7150	in	_
42-18	7151-7156	Table	_
42-19	7157-7158	2	_
42-20	7159-7160	.	_

Text=Participants were informed that both wager value and explosion probability increased with consecutive inflations; the rate of increase was not described.
43-1	7161-7173	Participants	_
43-2	7174-7178	were	_
43-3	7179-7187	informed	_
43-4	7188-7192	that	_
43-5	7193-7197	both	_
43-6	7198-7203	wager	_
43-7	7204-7209	value	_
43-8	7210-7213	and	_
43-9	7214-7223	explosion	_
43-10	7224-7235	probability	_
43-11	7236-7245	increased	_
43-12	7246-7250	with	_
43-13	7251-7262	consecutive	_
43-14	7263-7273	inflations	_
43-15	7274-7275	;	_
43-16	7276-7279	the	_
43-17	7280-7284	rate	_
43-18	7285-7287	of	_
43-19	7288-7296	increase	_
43-20	7297-7300	was	_
43-21	7301-7304	not	_
43-22	7305-7314	described	_
43-23	7315-7316	.	_

Text=Participants completed two 8-min blocks per timepoint, each with an average of 17 inflation sequences (SD = 2) and 96 decisions (SD = 9) per block; participants were unaware that the number of balloons per block was unlimited.
44-1	7317-7329	Participants	_
44-2	7330-7339	completed	_
44-3	7340-7343	two	_
44-4	7344-7349	8-min	_
44-5	7350-7356	blocks	_
44-6	7357-7360	per	_
44-7	7361-7370	timepoint	_
44-8	7371-7372	,	_
44-9	7373-7377	each	_
44-10	7378-7382	with	_
44-11	7383-7385	an	_
44-12	7386-7393	average	_
44-13	7394-7396	of	_
44-14	7397-7399	17	_
44-15	7400-7409	inflation	_
44-16	7410-7419	sequences	_
44-17	7420-7421	(	_
44-18	7422-7424	SD	_
44-19	7425-7426	=	_
44-20	7427-7428	2	_
44-21	7429-7430	)	_
44-22	7431-7434	and	_
44-23	7435-7437	96	_
44-24	7438-7447	decisions	_
44-25	7448-7449	(	_
44-26	7450-7452	SD	_
44-27	7453-7454	=	_
44-28	7455-7456	9	_
44-29	7457-7458	)	_
44-30	7459-7462	per	_
44-31	7463-7468	block	_
44-32	7469-7470	;	_
44-33	7471-7483	participants	_
44-34	7484-7488	were	_
44-35	7489-7496	unaware	_
44-36	7497-7501	that	_
44-37	7502-7505	the	_
44-38	7506-7512	number	_
44-39	7513-7515	of	_
44-40	7516-7524	balloons	_
44-41	7525-7528	per	_
44-42	7529-7534	block	_
44-43	7535-7538	was	_
44-44	7539-7548	unlimited	_
44-45	7549-7550	.	_

Text=Winnings were reset at the beginning of each block; participants received a monetary bonus equal to 25% of total earnings at each timepoint.
45-1	7551-7559	Winnings	_
45-2	7560-7564	were	_
45-3	7565-7570	reset	_
45-4	7571-7573	at	_
45-5	7574-7577	the	_
45-6	7578-7587	beginning	_
45-7	7588-7590	of	_
45-8	7591-7595	each	_
45-9	7596-7601	block	_
45-10	7602-7603	;	_
45-11	7604-7616	participants	_
45-12	7617-7625	received	_
45-13	7626-7627	a	_
45-14	7628-7636	monetary	_
45-15	7637-7642	bonus	_
45-16	7643-7648	equal	_
45-17	7649-7651	to	_
45-18	7652-7654	25	_
45-19	7655-7656	%	_
45-20	7657-7659	of	_
45-21	7660-7665	total	_
45-22	7666-7674	earnings	_
45-23	7675-7677	at	_
45-24	7678-7682	each	_
45-25	7683-7692	timepoint	_
45-26	7693-7694	.	_

Text=While it was possible for participants to produce a different number of events for entry into the first-level GLM at each timepoint, participants generated a similar number of events of each type (see Supplementary Table 2).
46-1	7695-7700	While	_
46-2	7701-7703	it	_
46-3	7704-7707	was	_
46-4	7708-7716	possible	_
46-5	7717-7720	for	_
46-6	7721-7733	participants	_
46-7	7734-7736	to	_
46-8	7737-7744	produce	_
46-9	7745-7746	a	_
46-10	7747-7756	different	_
46-11	7757-7763	number	_
46-12	7764-7766	of	_
46-13	7767-7773	events	_
46-14	7774-7777	for	_
46-15	7778-7783	entry	_
46-16	7784-7788	into	_
46-17	7789-7792	the	_
46-18	7793-7804	first-level	_
46-19	7805-7808	GLM	_
46-20	7809-7811	at	_
46-21	7812-7816	each	_
46-22	7817-7826	timepoint	_
46-23	7827-7828	,	_
46-24	7829-7841	participants	_
46-25	7842-7851	generated	_
46-26	7852-7853	a	_
46-27	7854-7861	similar	_
46-28	7862-7868	number	_
46-29	7869-7871	of	_
46-30	7872-7878	events	_
46-31	7879-7881	of	_
46-32	7882-7886	each	_
46-33	7887-7891	type	_
46-34	7892-7893	(	_
46-35	7894-7897	see	_
46-36	7898-7911	Supplementary	_
46-37	7912-7917	Table	_
46-38	7918-7919	2	_
46-39	7920-7921	)	_
46-40	7922-7923	.	_

Text=2.3.
47-1	7924-7927	2.3	_
47-2	7928-7929	.	_

Text=Preprocessing and analysis of neuroimaging data Preprocessing steps were identical to those reported by and are described in Supplementary materials.
48-1	7930-7943	Preprocessing	_
48-2	7944-7947	and	_
48-3	7948-7956	analysis	_
48-4	7957-7959	of	_
48-5	7960-7972	neuroimaging	_
48-6	7973-7977	data	_
48-7	7978-7991	Preprocessing	_
48-8	7992-7997	steps	_
48-9	7998-8002	were	_
48-10	8003-8012	identical	_
48-11	8013-8015	to	_
48-12	8016-8021	those	_
48-13	8022-8030	reported	_
48-14	8031-8033	by	_
48-15	8034-8037	and	_
48-16	8038-8041	are	_
48-17	8042-8051	described	_
48-18	8052-8054	in	_
48-19	8055-8068	Supplementary	_
48-20	8069-8078	materials	_
48-21	8079-8080	.	_

Text=Functional images from both timepoints were coregistered to the high resolution structural from baseline.
49-1	8081-8091	Functional	_
49-2	8092-8098	images	_
49-3	8099-8103	from	_
49-4	8104-8108	both	_
49-5	8109-8119	timepoints	_
49-6	8120-8124	were	_
49-7	8125-8137	coregistered	_
49-8	8138-8140	to	_
49-9	8141-8144	the	_
49-10	8145-8149	high	_
49-11	8150-8160	resolution	_
49-12	8161-8171	structural	_
49-13	8172-8176	from	_
49-14	8177-8185	baseline	_
49-15	8186-8187	.	_

Text=First- and second-level statistical analyses were conducted in SPM5.
50-1	8188-8194	First-	_
50-2	8195-8198	and	_
50-3	8199-8211	second-level	_
50-4	8212-8223	statistical	_
50-5	8224-8232	analyses	_
50-6	8233-8237	were	_
50-7	8238-8247	conducted	_
50-8	8248-8250	in	_
50-9	8251-8255	SPM5	_
50-10	8256-8257	.	_

Text=Event-related BOLD responses during the BART were estimated using a GLM with a global constant and 20 regressors for each timepoint (baseline vs. follow-up): six motion regressors, two constant terms, five basic (i.e., main effect) event regressors (i.e., 'Redeem', 'Inflate', 'Explode', 'Success', and 'Win'), five parametric modulators representing explosion probability for each event, and 2 parametric modulators representing response time (RT) for 'Redeem' and 'Inflate' events.
51-1	8258-8271	Event-related	_
51-2	8272-8276	BOLD	_
51-3	8277-8286	responses	_
51-4	8287-8293	during	_
51-5	8294-8297	the	_
51-6	8298-8302	BART	_
51-7	8303-8307	were	_
51-8	8308-8317	estimated	_
51-9	8318-8323	using	_
51-10	8324-8325	a	_
51-11	8326-8329	GLM	_
51-12	8330-8334	with	_
51-13	8335-8336	a	_
51-14	8337-8343	global	_
51-15	8344-8352	constant	_
51-16	8353-8356	and	_
51-17	8357-8359	20	_
51-18	8360-8370	regressors	_
51-19	8371-8374	for	_
51-20	8375-8379	each	_
51-21	8380-8389	timepoint	_
51-22	8390-8391	(	_
51-23	8392-8400	baseline	_
51-24	8401-8404	vs.	_
51-25	8405-8414	follow-up	_
51-26	8415-8416	)	_
51-27	8417-8418	:	_
51-28	8419-8422	six	_
51-29	8423-8429	motion	_
51-30	8430-8440	regressors	_
51-31	8441-8442	,	_
51-32	8443-8446	two	_
51-33	8447-8455	constant	_
51-34	8456-8461	terms	_
51-35	8462-8463	,	_
51-36	8464-8468	five	_
51-37	8469-8474	basic	_
51-38	8475-8476	(	_
51-39	8477-8481	i.e.	_
51-40	8482-8483	,	_
51-41	8484-8488	main	_
51-42	8489-8495	effect	_
51-43	8496-8497	)	_
51-44	8498-8503	event	_
51-45	8504-8514	regressors	_
51-46	8515-8516	(	_
51-47	8517-8521	i.e.	_
51-48	8522-8523	,	_
51-49	8524-8531	'Redeem	_
51-50	8532-8533	'	_
51-51	8534-8535	,	_
51-52	8536-8544	'Inflate	_
51-53	8545-8546	'	_
51-54	8547-8548	,	_
51-55	8549-8557	'Explode	_
51-56	8558-8559	'	_
51-57	8560-8561	,	_
51-58	8562-8570	'Success	_
51-59	8571-8572	'	_
51-60	8573-8574	,	_
51-61	8575-8578	and	_
51-62	8579-8583	'Win	_
51-63	8584-8585	'	_
51-64	8586-8587	)	_
51-65	8588-8589	,	_
51-66	8590-8594	five	_
51-67	8595-8605	parametric	_
51-68	8606-8616	modulators	_
51-69	8617-8629	representing	_
51-70	8630-8639	explosion	_
51-71	8640-8651	probability	_
51-72	8652-8655	for	_
51-73	8656-8660	each	_
51-74	8661-8666	event	_
51-75	8667-8668	,	_
51-76	8669-8672	and	_
51-77	8673-8674	2	_
51-78	8675-8685	parametric	_
51-79	8686-8696	modulators	_
51-80	8697-8709	representing	_
51-81	8710-8718	response	_
51-82	8719-8723	time	_
51-83	8724-8725	(	_
51-84	8726-8728	RT	_
51-85	8729-8730	)	_
51-86	8731-8734	for	_
51-87	8735-8742	'Redeem	_
51-88	8743-8744	'	_
51-89	8745-8748	and	_
51-90	8749-8757	'Inflate	_
51-91	8758-8759	'	_
51-92	8760-8766	events	_
51-93	8767-8768	.	_

Text=A canonical hemodynamic response function was used to model BOLD response, with decision-related regressors time-locked to RT and outcome-related regressors time-locked to feedback latency.
52-1	8769-8770	A	_
52-2	8771-8780	canonical	_
52-3	8781-8792	hemodynamic	_
52-4	8793-8801	response	_
52-5	8802-8810	function	_
52-6	8811-8814	was	_
52-7	8815-8819	used	_
52-8	8820-8822	to	_
52-9	8823-8828	model	_
52-10	8829-8833	BOLD	_
52-11	8834-8842	response	_
52-12	8843-8844	,	_
52-13	8845-8849	with	_
52-14	8850-8866	decision-related	_
52-15	8867-8877	regressors	_
52-16	8878-8889	time-locked	_
52-17	8890-8892	to	_
52-18	8893-8895	RT	_
52-19	8896-8899	and	_
52-20	8900-8915	outcome-related	_
52-21	8916-8926	regressors	_
52-22	8927-8938	time-locked	_
52-23	8939-8941	to	_
52-24	8942-8950	feedback	_
52-25	8951-8958	latency	_
52-26	8959-8960	.	_

Text=Due to the relationship between risk and reward in the task, parametric modulators specified with reference to explosion probability also tracked trial-to-trial variation in reward magnitude.
53-1	8961-8964	Due	_
53-2	8965-8967	to	_
53-3	8968-8971	the	_
53-4	8972-8984	relationship	_
53-5	8985-8992	between	_
53-6	8993-8997	risk	_
53-7	8998-9001	and	_
53-8	9002-9008	reward	_
53-9	9009-9011	in	_
53-10	9012-9015	the	_
53-11	9016-9020	task	_
53-12	9021-9022	,	_
53-13	9023-9033	parametric	_
53-14	9034-9044	modulators	_
53-15	9045-9054	specified	_
53-16	9055-9059	with	_
53-17	9060-9069	reference	_
53-18	9070-9072	to	_
53-19	9073-9082	explosion	_
53-20	9083-9094	probability	_
53-21	9095-9099	also	_
53-22	9100-9107	tracked	_
53-23	9108-9122	trial-to-trial	_
53-24	9123-9132	variation	_
53-25	9133-9135	in	_
53-26	9136-9142	reward	_
53-27	9143-9152	magnitude	_
53-28	9153-9154	.	_

Text=These parametrically-modulated regressors were identical to the five basic event regressors, except that the magnitude of each modeled event was multiplied by that event's explosion probability.
54-1	9155-9160	These	_
54-2	9161-9185	parametrically-modulated	_
54-3	9186-9196	regressors	_
54-4	9197-9201	were	_
54-5	9202-9211	identical	_
54-6	9212-9214	to	_
54-7	9215-9218	the	_
54-8	9219-9223	five	_
54-9	9224-9229	basic	_
54-10	9230-9235	event	_
54-11	9236-9246	regressors	_
54-12	9247-9248	,	_
54-13	9249-9255	except	_
54-14	9256-9260	that	_
54-15	9261-9264	the	_
54-16	9265-9274	magnitude	_
54-17	9275-9277	of	_
54-18	9278-9282	each	_
54-19	9283-9290	modeled	_
54-20	9291-9296	event	_
54-21	9297-9300	was	_
54-22	9301-9311	multiplied	_
54-23	9312-9314	by	_
54-24	9315-9319	that	_
54-25	9320-9325	event	_
54-26	9326-9328	's	_
54-27	9329-9338	explosion	_
54-28	9339-9350	probability	_
54-29	9351-9352	.	_

Text=Each parametrically-modulated regressor was mean-centered, so that the sum of regressor values across all time points was zero.
55-1	9353-9357	Each	_
55-2	9358-9382	parametrically-modulated	_
55-3	9383-9392	regressor	_
55-4	9393-9396	was	_
55-5	9397-9410	mean-centered	_
55-6	9411-9412	,	_
55-7	9413-9415	so	_
55-8	9416-9420	that	_
55-9	9421-9424	the	_
55-10	9425-9428	sum	_
55-11	9429-9431	of	_
55-12	9432-9441	regressor	_
55-13	9442-9448	values	_
55-14	9449-9455	across	_
55-15	9456-9459	all	_
55-16	9460-9464	time	_
55-17	9465-9471	points	_
55-18	9472-9475	was	_
55-19	9476-9480	zero	_
55-20	9481-9482	.	_

Text=For three participants, a lower occurrence of explosions precluded unique estimation of basic event regressors and parametric modulators for 'Explode' events; this was additionally the case for one participant for 'Win' events.
56-1	9483-9486	For	_
56-2	9487-9492	three	_
56-3	9493-9505	participants	_
56-4	9506-9507	,	_
56-5	9508-9509	a	_
56-6	9510-9515	lower	_
56-7	9516-9526	occurrence	_
56-8	9527-9529	of	_
56-9	9530-9540	explosions	_
56-10	9541-9550	precluded	_
56-11	9551-9557	unique	_
56-12	9558-9568	estimation	_
56-13	9569-9571	of	_
56-14	9572-9577	basic	_
56-15	9578-9583	event	_
56-16	9584-9594	regressors	_
56-17	9595-9598	and	_
56-18	9599-9609	parametric	_
56-19	9610-9620	modulators	_
56-20	9621-9624	for	_
56-21	9625-9633	'Explode	_
56-22	9634-9635	'	_
56-23	9636-9642	events	_
56-24	9643-9644	;	_
56-25	9645-9649	this	_
56-26	9650-9653	was	_
56-27	9654-9666	additionally	_
56-28	9667-9670	the	_
56-29	9671-9675	case	_
56-30	9676-9679	for	_
56-31	9680-9683	one	_
56-32	9684-9695	participant	_
56-33	9696-9699	for	_
56-34	9700-9704	'Win	_
56-35	9705-9706	'	_
56-36	9707-9713	events	_
56-37	9714-9715	.	_

Text=These participants were accordingly excluded from parametric modulator contrasts of each corresponding type.
57-1	9716-9721	These	_
57-2	9722-9734	participants	_
57-3	9735-9739	were	_
57-4	9740-9751	accordingly	_
57-5	9752-9760	excluded	_
57-6	9761-9765	from	_
57-7	9766-9776	parametric	_
57-8	9777-9786	modulator	_
57-9	9787-9796	contrasts	_
57-10	9797-9799	of	_
57-11	9800-9804	each	_
57-12	9805-9818	corresponding	_
57-13	9819-9823	type	_
57-14	9824-9825	.	_

Text=Given our hypotheses, only the five parametric modulators representing explosion probability (designated by' * p (Explode)') were considered in second-level analyses.
58-1	9826-9831	Given	_
58-2	9832-9835	our	_
58-3	9836-9846	hypotheses	_
58-4	9847-9848	,	_
58-5	9849-9853	only	_
58-6	9854-9857	the	_
58-7	9858-9862	five	_
58-8	9863-9873	parametric	_
58-9	9874-9884	modulators	_
58-10	9885-9897	representing	_
58-11	9898-9907	explosion	_
58-12	9908-9919	probability	_
58-13	9920-9921	(	_
58-14	9922-9932	designated	_
58-15	9933-9935	by	_
58-16	9936-9937	'	_
58-17	9938-9939	*	_
58-18	9940-9941	p	_
58-19	9942-9943	(	_
58-20	9944-9951	Explode	_
58-21	9952-9953	)	_
58-22	9954-9955	'	_
58-23	9956-9957	)	_
58-24	9958-9962	were	_
58-25	9963-9973	considered	_
58-26	9974-9976	in	_
58-27	9977-9989	second-level	_
58-28	9990-9998	analyses	_
58-29	9999-10000	.	_

Text=We specifically explored longitudinal change in parametric modulators by computing longitudinal contrasts (i.e., 3-month follow-up – baseline, hereafter FU-BL) and evaluating these contrasts using one-sample t-tests to assess main effects and correlation analyses to assess longitudinal change related to substance use outcomes (represented by the SUM).
59-1	10001-10003	We	_
59-2	10004-10016	specifically	_
59-3	10017-10025	explored	_
59-4	10026-10038	longitudinal	_
59-5	10039-10045	change	_
59-6	10046-10048	in	_
59-7	10049-10059	parametric	_
59-8	10060-10070	modulators	_
59-9	10071-10073	by	_
59-10	10074-10083	computing	_
59-11	10084-10096	longitudinal	_
59-12	10097-10106	contrasts	_
59-13	10107-10108	(	_
59-14	10109-10113	i.e.	_
59-15	10114-10115	,	_
59-16	10116-10123	3-month	_
59-17	10124-10133	follow-up	_
59-18	10134-10135	–	_
59-19	10136-10144	baseline	_
59-20	10145-10146	,	_
59-21	10147-10156	hereafter	_
59-22	10157-10162	FU-BL	_
59-23	10163-10164	)	_
59-24	10165-10168	and	_
59-25	10169-10179	evaluating	_
59-26	10180-10185	these	_
59-27	10186-10195	contrasts	_
59-28	10196-10201	using	_
59-29	10202-10212	one-sample	_
59-30	10213-10220	t-tests	_
59-31	10221-10223	to	_
59-32	10224-10230	assess	_
59-33	10231-10235	main	_
59-34	10236-10243	effects	_
59-35	10244-10247	and	_
59-36	10248-10259	correlation	_
59-37	10260-10268	analyses	_
59-38	10269-10271	to	_
59-39	10272-10278	assess	_
59-40	10279-10291	longitudinal	_
59-41	10292-10298	change	_
59-42	10299-10306	related	_
59-43	10307-10309	to	_
59-44	10310-10319	substance	_
59-45	10320-10323	use	_
59-46	10324-10332	outcomes	_
59-47	10333-10334	(	_
59-48	10335-10346	represented	_
59-49	10347-10349	by	_
59-50	10350-10353	the	_
59-51	10354-10357	SUM	_
59-52	10358-10359	)	_
59-53	10360-10361	.	_

Text=Longitudinal contrasts were specified at the first-level and tested at the second-level with random effects to model between-subjects variance.
60-1	10362-10374	Longitudinal	_
60-2	10375-10384	contrasts	_
60-3	10385-10389	were	_
60-4	10390-10399	specified	_
60-5	10400-10402	at	_
60-6	10403-10406	the	_
60-7	10407-10418	first-level	_
60-8	10419-10422	and	_
60-9	10423-10429	tested	_
60-10	10430-10432	at	_
60-11	10433-10436	the	_
60-12	10437-10449	second-level	_
60-13	10450-10454	with	_
60-14	10455-10461	random	_
60-15	10462-10469	effects	_
60-16	10470-10472	to	_
60-17	10473-10478	model	_
60-18	10479-10495	between-subjects	_
60-19	10496-10504	variance	_
60-20	10505-10506	.	_

Text=To exclude effects related to behavior change between sessions, the difference in mean BART inflation number between acquisition sessions (FU-BL) was included as a nuisance covariate at the second-level.
61-1	10507-10509	To	_
61-2	10510-10517	exclude	_
61-3	10518-10525	effects	_
61-4	10526-10533	related	_
61-5	10534-10536	to	_
61-6	10537-10545	behavior	_
61-7	10546-10552	change	_
61-8	10553-10560	between	_
61-9	10561-10569	sessions	_
61-10	10570-10571	,	_
61-11	10572-10575	the	_
61-12	10576-10586	difference	_
61-13	10587-10589	in	_
61-14	10590-10594	mean	_
61-15	10595-10599	BART	_
61-16	10600-10609	inflation	_
61-17	10610-10616	number	_
61-18	10617-10624	between	_
61-19	10625-10636	acquisition	_
61-20	10637-10645	sessions	_
61-21	10646-10647	(	_
61-22	10648-10653	FU-BL	_
61-23	10654-10655	)	_
61-24	10656-10659	was	_
61-25	10660-10668	included	_
61-26	10669-10671	as	_
61-27	10672-10673	a	_
61-28	10674-10682	nuisance	_
61-29	10683-10692	covariate	_
61-30	10693-10695	at	_
61-31	10696-10699	the	_
61-32	10700-10712	second-level	_
61-33	10713-10714	.	_

Text=Reported p-values for second-level analyses reflect one-tailed tests of significance.
62-1	10715-10723	Reported	_
62-2	10724-10732	p-values	_
62-3	10733-10736	for	_
62-4	10737-10749	second-level	_
62-5	10750-10758	analyses	_
62-6	10759-10766	reflect	_
62-7	10767-10777	one-tailed	_
62-8	10778-10783	tests	_
62-9	10784-10786	of	_
62-10	10787-10799	significance	_
62-11	10800-10801	.	_

Text=In order to test predictions from the Inflate * p (Explode) FU-BL contrast was specified to identify regions wherein longitudinal signal increased with escalating risk/reward during decision-making and the Success * p (Explode) FU-BL contrast was specified to identify regions with less signal to high-risk reward over time.
63-1	10802-10804	In	_
63-2	10805-10810	order	_
63-3	10811-10813	to	_
63-4	10814-10818	test	_
63-5	10819-10830	predictions	_
63-6	10831-10835	from	_
63-7	10836-10839	the	_
63-8	10840-10847	Inflate	_
63-9	10848-10849	*	_
63-10	10850-10851	p	_
63-11	10852-10853	(	_
63-12	10854-10861	Explode	_
63-13	10862-10863	)	_
63-14	10864-10869	FU-BL	_
63-15	10870-10878	contrast	_
63-16	10879-10882	was	_
63-17	10883-10892	specified	_
63-18	10893-10895	to	_
63-19	10896-10904	identify	_
63-20	10905-10912	regions	_
63-21	10913-10920	wherein	_
63-22	10921-10933	longitudinal	_
63-23	10934-10940	signal	_
63-24	10941-10950	increased	_
63-25	10951-10955	with	_
63-26	10956-10966	escalating	_
63-27	10967-10978	risk/reward	_
63-28	10979-10985	during	_
63-29	10986-11001	decision-making	_
63-30	11002-11005	and	_
63-31	11006-11009	the	_
63-32	11010-11017	Success	_
63-33	11018-11019	*	_
63-34	11020-11021	p	_
63-35	11022-11023	(	_
63-36	11024-11031	Explode	_
63-37	11032-11033	)	_
63-38	11034-11039	FU-BL	_
63-39	11040-11048	contrast	_
63-40	11049-11052	was	_
63-41	11053-11062	specified	_
63-42	11063-11065	to	_
63-43	11066-11074	identify	_
63-44	11075-11082	regions	_
63-45	11083-11087	with	_
63-46	11088-11092	less	_
63-47	11093-11099	signal	_
63-48	11100-11102	to	_
63-49	11103-11112	high-risk	_
63-50	11113-11119	reward	_
63-51	11120-11124	over	_
63-52	11125-11129	time	_
63-53	11130-11131	.	_

Text=Longitudinal contrasts were similarly specified for Explode * p (Explode), Win * p (Explode), and Redeem * p (Explode) parametric modulators.
64-1	11132-11144	Longitudinal	_
64-2	11145-11154	contrasts	_
64-3	11155-11159	were	_
64-4	11160-11169	similarly	_
64-5	11170-11179	specified	_
64-6	11180-11183	for	_
64-7	11184-11191	Explode	_
64-8	11192-11193	*	_
64-9	11194-11195	p	_
64-10	11196-11197	(	_
64-11	11198-11205	Explode	_
64-12	11206-11207	)	_
64-13	11208-11209	,	_
64-14	11210-11213	Win	_
64-15	11214-11215	*	_
64-16	11216-11217	p	_
64-17	11218-11219	(	_
64-18	11220-11227	Explode	_
64-19	11228-11229	)	_
64-20	11230-11231	,	_
64-21	11232-11235	and	_
64-22	11236-11242	Redeem	_
64-23	11243-11244	*	_
64-24	11245-11246	p	_
64-25	11247-11248	(	_
64-26	11249-11256	Explode	_
64-27	11257-11258	)	_
64-28	11259-11269	parametric	_
64-29	11270-11280	modulators	_
64-30	11281-11282	.	_

Text=Between-subject, whole-brain correlational analyses were conducted for longitudinal contrasts to identify regions wherein changes in task-related signal related to substance use outcomes (i.e., SUM).
65-1	11283-11298	Between-subject	_
65-2	11299-11300	,	_
65-3	11301-11312	whole-brain	_
65-4	11313-11326	correlational	_
65-5	11327-11335	analyses	_
65-6	11336-11340	were	_
65-7	11341-11350	conducted	_
65-8	11351-11354	for	_
65-9	11355-11367	longitudinal	_
65-10	11368-11377	contrasts	_
65-11	11378-11380	to	_
65-12	11381-11389	identify	_
65-13	11390-11397	regions	_
65-14	11398-11405	wherein	_
65-15	11406-11413	changes	_
65-16	11414-11416	in	_
65-17	11417-11429	task-related	_
65-18	11430-11436	signal	_
65-19	11437-11444	related	_
65-20	11445-11447	to	_
65-21	11448-11457	substance	_
65-22	11458-11461	use	_
65-23	11462-11470	outcomes	_
65-24	11471-11472	(	_
65-25	11473-11477	i.e.	_
65-26	11478-11479	,	_
65-27	11480-11483	SUM	_
65-28	11484-11485	)	_
65-29	11486-11487	.	_

Text=Negative correlations represent less use with increased parametrically-modulated event-related activation at follow-up, relative to baseline.
66-1	11488-11496	Negative	_
66-2	11497-11509	correlations	_
66-3	11510-11519	represent	_
66-4	11520-11524	less	_
66-5	11525-11528	use	_
66-6	11529-11533	with	_
66-7	11534-11543	increased	_
66-8	11544-11568	parametrically-modulated	_
66-9	11569-11582	event-related	_
66-10	11583-11593	activation	_
66-11	11594-11596	at	_
66-12	11597-11606	follow-up	_
66-13	11607-11608	,	_
66-14	11609-11617	relative	_
66-15	11618-11620	to	_
66-16	11621-11629	baseline	_
66-17	11630-11631	.	_

Text=Positive correlations indicate that increased parametrically-modulated signal at follow-up corresponded with more use.
67-1	11632-11640	Positive	_
67-2	11641-11653	correlations	_
67-3	11654-11662	indicate	_
67-4	11663-11667	that	_
67-5	11668-11677	increased	_
67-6	11678-11702	parametrically-modulated	_
67-7	11703-11709	signal	_
67-8	11710-11712	at	_
67-9	11713-11722	follow-up	_
67-10	11723-11735	corresponded	_
67-11	11736-11740	with	_
67-12	11741-11745	more	_
67-13	11746-11749	use	_
67-14	11750-11751	.	_

Text=We employed a whole brain search space to improve hypothesis-generating potential; however, our hypotheses specifically concerned mPFC/ACC, justifying small volume correction for that region.
68-1	11752-11754	We	_
68-2	11755-11763	employed	_
68-3	11764-11765	a	_
68-4	11766-11771	whole	_
68-5	11772-11777	brain	_
68-6	11778-11784	search	_
68-7	11785-11790	space	_
68-8	11791-11793	to	_
68-9	11794-11801	improve	_
68-10	11802-11823	hypothesis-generating	_
68-11	11824-11833	potential	_
68-12	11834-11835	;	_
68-13	11836-11843	however	_
68-14	11844-11845	,	_
68-15	11846-11849	our	_
68-16	11850-11860	hypotheses	_
68-17	11861-11873	specifically	_
68-18	11874-11883	concerned	_
68-19	11884-11892	mPFC/ACC	_
68-20	11893-11894	,	_
68-21	11895-11905	justifying	_
68-22	11906-11911	small	_
68-23	11912-11918	volume	_
68-24	11919-11929	correction	_
68-25	11930-11933	for	_
68-26	11934-11938	that	_
68-27	11939-11945	region	_
68-28	11946-11947	.	_

Text=Clusters of 30 or more contiguous voxels, passing cluster-level correction at the 0.05 α-level (initial cluster-forming threshold of 0.001; cluster extent estimated using AFNI's 3dClustSim to achieve a type I error rate of 0.5%), were identified as regions of interest.
69-1	11948-11956	Clusters	_
69-2	11957-11959	of	_
69-3	11960-11962	30	_
69-4	11963-11965	or	_
69-5	11966-11970	more	_
69-6	11971-11981	contiguous	_
69-7	11982-11988	voxels	_
69-8	11989-11990	,	_
69-9	11991-11998	passing	_
69-10	11999-12012	cluster-level	_
69-11	12013-12023	correction	_
69-12	12024-12026	at	_
69-13	12027-12030	the	_
69-14	12031-12035	0.05	_
69-15	12036-12043	α-level	_
69-16	12044-12045	(	_
69-17	12046-12053	initial	_
69-18	12054-12069	cluster-forming	_
69-19	12070-12079	threshold	_
69-20	12080-12082	of	_
69-21	12083-12088	0.001	_
69-22	12089-12090	;	_
69-23	12091-12098	cluster	_
69-24	12099-12105	extent	_
69-25	12106-12115	estimated	_
69-26	12116-12121	using	_
69-27	12122-12126	AFNI	_
69-28	12127-12129	's	_
69-29	12130-12140	3dClustSim	_
69-30	12141-12143	to	_
69-31	12144-12151	achieve	_
69-32	12152-12153	a	_
69-33	12154-12158	type	_
69-34	12159-12160	I	_
69-35	12161-12166	error	_
69-36	12167-12171	rate	_
69-37	12172-12174	of	_
69-38	12175-12178	0.5	_
69-39	12179-12180	%	_
69-40	12181-12182	)	_
69-41	12183-12184	,	_
69-42	12185-12189	were	_
69-43	12190-12200	identified	_
69-44	12201-12203	as	_
69-45	12204-12211	regions	_
69-46	12212-12214	of	_
69-47	12215-12223	interest	_
69-48	12224-12225	.	_

Text=Bonferroni correction was additionally applied for 10 whole brain correlations (5 positive and 5 negative longitudinal contrast correlations), lowering the cluster-corrected p-value to 0.005 for these comparisons.
70-1	12226-12236	Bonferroni	_
70-2	12237-12247	correction	_
70-3	12248-12251	was	_
70-4	12252-12264	additionally	_
70-5	12265-12272	applied	_
70-6	12273-12276	for	_
70-7	12277-12279	10	_
70-8	12280-12285	whole	_
70-9	12286-12291	brain	_
70-10	12292-12304	correlations	_
70-11	12305-12306	(	_
70-12	12307-12308	5	_
70-13	12309-12317	positive	_
70-14	12318-12321	and	_
70-15	12322-12323	5	_
70-16	12324-12332	negative	_
70-17	12333-12345	longitudinal	_
70-18	12346-12354	contrast	_
70-19	12355-12367	correlations	_
70-20	12368-12369	)	_
70-21	12370-12371	,	_
70-22	12372-12380	lowering	_
70-23	12381-12384	the	_
70-24	12385-12402	cluster-corrected	_
70-25	12403-12410	p-value	_
70-26	12411-12413	to	_
70-27	12414-12419	0.005	_
70-28	12420-12423	for	_
70-29	12424-12429	these	_
70-30	12430-12441	comparisons	_
70-31	12442-12443	.	_

Text=Correlation analyses were repeated following exclusion of participants with SUM scores exceeding 2 standard deviations of the mean to assess the influence of extreme values.
71-1	12444-12455	Correlation	_
71-2	12456-12464	analyses	_
71-3	12465-12469	were	_
71-4	12470-12478	repeated	_
71-5	12479-12488	following	_
71-6	12489-12498	exclusion	_
71-7	12499-12501	of	_
71-8	12502-12514	participants	_
71-9	12515-12519	with	_
71-10	12520-12523	SUM	_
71-11	12524-12530	scores	_
71-12	12531-12540	exceeding	_
71-13	12541-12542	2	_
71-14	12543-12551	standard	_
71-15	12552-12562	deviations	_
71-16	12563-12565	of	_
71-17	12566-12569	the	_
71-18	12570-12574	mean	_
71-19	12575-12577	to	_
71-20	12578-12584	assess	_
71-21	12585-12588	the	_
71-22	12589-12598	influence	_
71-23	12599-12601	of	_
71-24	12602-12609	extreme	_
71-25	12610-12616	values	_
71-26	12617-12618	.	_

Text=2.4.
72-1	12619-12622	2.4	_
72-2	12623-12624	.	_

Text=Cognitive-behavioral and self-report data Repeated-measures analysis of variance (ANOVA) was used to assess longitudinal change in BART performance, as well as self-report and cognitive-behavioral measures (see Supplementary materials).
73-1	12625-12645	Cognitive-behavioral	_
73-2	12646-12649	and	_
73-3	12650-12661	self-report	_
73-4	12662-12666	data	_
73-5	12667-12684	Repeated-measures	_
73-6	12685-12693	analysis	_
73-7	12694-12696	of	_
73-8	12697-12705	variance	_
73-9	12706-12707	(	_
73-10	12708-12713	ANOVA	_
73-11	12714-12715	)	_
73-12	12716-12719	was	_
73-13	12720-12724	used	_
73-14	12725-12727	to	_
73-15	12728-12734	assess	_
73-16	12735-12747	longitudinal	_
73-17	12748-12754	change	_
73-18	12755-12757	in	_
73-19	12758-12762	BART	_
73-20	12763-12774	performance	_
73-21	12775-12776	,	_
73-22	12777-12779	as	_
73-23	12780-12784	well	_
73-24	12785-12787	as	_
73-25	12788-12799	self-report	_
73-26	12800-12803	and	_
73-27	12804-12824	cognitive-behavioral	_
73-28	12825-12833	measures	_
73-29	12834-12835	(	_
73-30	12836-12839	see	_
73-31	12840-12853	Supplementary	_
73-32	12854-12863	materials	_
73-33	12864-12865	)	_
73-34	12866-12867	.	_

Text=Pearson correlations between SUM values and longitudinal change in these variables were also calculated.
74-1	12868-12875	Pearson	_
74-2	12876-12888	correlations	_
74-3	12889-12896	between	_
74-4	12897-12900	SUM	_
74-5	12901-12907	values	_
74-6	12908-12911	and	_
74-7	12912-12924	longitudinal	_
74-8	12925-12931	change	_
74-9	12932-12934	in	_
74-10	12935-12940	these	_
74-11	12941-12950	variables	_
74-12	12951-12955	were	_
74-13	12956-12960	also	_
74-14	12961-12971	calculated	_
74-15	12972-12973	.	_

Text=Post hoc paired t-tests were utilized for comparison of specific conditions.
75-1	12974-12978	Post	_
75-2	12979-12982	hoc	_
75-3	12983-12989	paired	_
75-4	12990-12997	t-tests	_
75-5	12998-13002	were	_
75-6	13003-13011	utilized	_
75-7	13012-13015	for	_
75-8	13016-13026	comparison	_
75-9	13027-13029	of	_
75-10	13030-13038	specific	_
75-11	13039-13049	conditions	_
75-12	13050-13051	.	_

Text=Reported p-values reflect a two-tailed test of significance.
76-1	13052-13060	Reported	_
76-2	13061-13069	p-values	_
76-3	13070-13077	reflect	_
76-4	13078-13079	a	_
76-5	13080-13090	two-tailed	_
76-6	13091-13095	test	_
76-7	13096-13098	of	_
76-8	13099-13111	significance	_
76-9	13112-13113	.	_

